In 1312 cancers with FGFR2 abnormalities, FGFR2 amplification was detected in 515 cases (39.2%), fusion in 280 cases (20.9%), and mutation in 568 cases (43.3%) (Figure 1). This evidence concerns the gene FGFR2 and cancer.